Symtuza for HIV-1 Treatment

Overview and Indication

The American Medical Association recommends Symtuza as an alternative initial therapy for treatment-naïve HIV-1 infected adults, particularly valuable for patients with known or suspected multidrug resistance 1

Symtuza is specifically positioned for treatment-naïve patients with known or suspected pretherapy multidrug resistance 1
The regimen has a high genetic barrier to resistance, with darunavir maintaining this advantage even with intermittent adherence 2

The Infectious Diseases Society of America recommends monitoring HIV RNA levels within the first 6 weeks, then every 3 months until <50 copies/mL for 1 year, then every 6 months 2
The society also recommends monitoring CD4 count every 6 months until >250/μL for 1 year, then can discontinue if virus remains suppressed 2

The American Medical Association notes that cobicistat is a strong CYP3A inhibitor, resulting in extensive drug interactions due to cobicistat boosting 1, 2
The association advises against using Symtuza with drugs highly dependent on CYP3A clearance with narrow therapeutic index 1, 2
The Centers for Disease Control and Prevention recommend avoiding Symtuza in patients taking proton pump inhibitors without careful consideration of drug interactions 2

The American College of Obstetricians and Gynecologists does not recommend Symtuza during pregnancy, as cobicistat-boosted darunavir achieves inadequate plasma levels 1, 2
If darunavir is required during pregnancy, the college suggests using ritonavir-boosted darunavir 600 mg twice daily instead 1

The Infectious Diseases Society of America notes that while integrase strand transfer inhibitor (InSTI)-based regimens remain the preferred initial therapy for most treatment-naïve patients, Symtuza fills a critical niche for patients with suspected or confirmed multidrug resistance 1